title: Patient selection for TAVI in 2014: is there a justification for treating low- or intermediate-risk patients? The surgeon's view.
abstract: The introduction of transcatheter aortic valve implantation (TAVI) has revolutionised the treatment of patients with symptomatic severe aortic valve stenosis (AS). In extreme and high-risk patients, randomised studies have shown the benefit of this new therapy. However, there are still a lot of unknowns, and the question has arisen whether it is justified to expand the indication of TAVI to other patient groups, especially intermediate-or even low-risk patients.
authors.affiliation: Department of Thoracic Surgery, Erasmus MC, Rotterdam, The Netherlands.
authors.forename: Arie Pieter
authors.initials: AP
authors.lastname: Kappetein
authors.forename: Ruben L J
authors.initials: RL
authors.lastname: Osnabrugge
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Head
mesh_terms: D001024:Aortic Valve Stenosis / Q000601:surgery*; D057510:Endovascular Procedures; D006801:Humans; D018579:Patient Selection; D013903:Thoracic Surgery / Q000639:trends*; D065467:Transcatheter Aortic Valve Replacement